Daratumumab (DARA) is an IgG1κ human monoclonal antibody (MAb) that binds to the CD38 protein, a surface protein that is expressed on MM cells, and inhibits the in vivo growth of CD38-expressing tumor cells. This evidence concerns the gene CD38 and Miyoshi myopathy.